Glucose homeostasis: roles of insulin, glucagon, amylin, and GLP-1.

Slides:

Advertisements

Similar presentations

Long-term Complications of Type 2 Diabetes

Advertisements

The role of glucagon and GLP-1 in the regulation of appetite. Katherine Simpson, Jennifer Parker, Niamh Martin, Ben Field, James Minnion, Mohammad Ghatei.

 GLP -1 (gut hormone) + GIP = incretin effect =Augmentation of insulin after oral glucose  Type 2 diabetics little incretin effect  Reduced GLP-1 secretion.

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association.

Faculty Disclosure Mikayla Spangler, PharmD, BCPS Dr. Spangler has listed no financial interest/arrangement that would be considered a conflict of interest.

DIABETES MEDICATION UPDATE A. Sami Wood, MS, RD/LD,CDE Center For Diabetes Education OSUMC.

Diabesity Management Colette Walter, NP. Objectives 1. Pharmacologic management and understanding of treatment related to the overweight diabetic patient.

Prescribing information can be found at the end of this slide deck.

Aims of the session: Learn about the control of blood glucose concentration. Be able to answer exam questions. Summarise the key points about this example.

GLP-1 Effectiveness, Mechanisms of Action and Potential Part 1.

Journal Club 2009 年 1 月 29 日（木） 8 ： 20 ～ 8 ： 50 B 棟 8 階カンファレンスルーム薬剤部 TTSP 石井英俊.

Metabolic disorders after Stroke Dr David Strain Peninsula Medical School Royal Devon & Exeter Hospital.

The role of GLP-1 in mediating the anorectic and metabolic effects of bariatric surgery. David D’Alessio, MD Division of Endocrinology University of Cincinnati.

Diabetes Update Part 2 of 3 Division of Endocrinology

GLP-1 Effectiveness, Mechanisms of Action and Potential Part 2.

GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 7.

SGLT-2 Inhibitor with Incretins.

JANUVIA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. JANUVIA Tablets contain sitagliptin.

 GLP-1 agonists have shown to help patients lose weight  Mechanism of GLP-1 agonists  Cardioprotective effects of GLP-1 agonists  GLP-1 agonists and.

Pramlintide – An analog of amylin that overcomes the tendency of human amylin to: Aggregate, form insoluble particles Adhere to surfaces – Pharmacokinetic.

به نام خدا.

Hypoglycemia & Hyperglycemia Dave Joffe, BSPharm, CDE, FACA.

Diabetes. The Food You Eat is Broken Down Into Glucose to Supply Energy to Your Cells.

GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 4.

Metabolic GI peptide hormones Ghrelin Insulin Glucagon Insulin Glucagon GIP GLP-1 Insulin Leptin Insulin Adiposity tissue insulin Insulin.

In the name of God.

Glucose Metabolism Dr Lenon T Gwaunza MBChB, BSc (Hons), MSc (UCL)

GLP-1 agonists Ian Gallen Consultant Community Diabetologist

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions?

Endocrine System.

Glucose homeostasis: roles of insulin and glucagon. 1A.

Pramlintide is a synthetic hormone given SC resembling human amylin effects It reduces the production of glucose by the liver by inhibiting the action.

Safia Costes, Peter C. Butler Cell Metabolism

Pramlintide Synthetic analog of the β-cell hormone amylin

Insulin and glucagon secretion: nondiabetic and diabetic subjects.

GLP-1 Agonists and DPP-4 Inhibitors How do they work?

Aims of the session: Learn about the control of blood glucose concentration. Be able to answer exam questions. Summarise the key points about this example.

Volume 141, Issue 3, Pages (September 2011)

Background What is a hormone?

Postprandial glucose flux in nondiabetic controls.

Volume 150, Issue 2, Pages (February 2016)

Update on cystic fibrosis-related diabetes

Figure 1 Sites of action of glucose-lowering agents

GLP-1 Agonists and DPP-4 Inhibitors How do they work?

GLP-1 Agonists and DPP-4 Inhibitors How do they work?

Carbohydrate absorption inhibitors α-glucosidose inhibitors

Range of mean changes from baseline in body weight in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor.

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 6.

VAN GLP-1R kd disturbed postmeal glycemia and insulinemia but did not impair tolerance of an oral glucose bolus. VAN GLP-1R kd disturbed postmeal glycemia.

Incretin Physiology in Type 2 Diabetes Mellitus

A working hypothesis for insulin action in the brain.

Changes (mean +SEM) in glucose, insulin, glucagon-like peptide (GLP)-1 and ghrelin from the baseline values after administration of placebo (broken lines.

Left columns: Plasma glucose and serum insulin concentrations, circulating TF-PCA, and FVIIa activity before and during 24 h of selective hyperglycemia.

ΑGLP-1R−/− mice show glucose intolerance and disturbed glucagon secretion in response to i.p. glucose administration. αGLP-1R−/− mice show glucose intolerance.

The effect of VSG on body weight and body fat in GLP-1r KO mice.

ATL-801 treatment increases insulin sensitivity in KKAY mice.

Rapid improvement of glucose tolerance induced by PP

Glucose stimulates GLP-1 secretion from the perfused rat intestine by a dose- and absorption-dependent manner. Glucose stimulates GLP-1 secretion from.

Mean (±SE) plasma glucose concentrations before, during, and after infusions of octreotide (with growth hormone) with saline (•), with insulin replacement.

Model for central nervous system regulation of insulin secretion and insulin sensitivity via the SNS during cold exposure. Model for central nervous system.

Food intake in response to central infusion of glucose (squares) or insulin (triangles) and in response to successive central infusion of insulin, insulin.

PKA inhibitors do not markedly affect the potentiation of glucose-induced insulin release by GLP-1. PKA inhibitors do not markedly affect the potentiation.

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 7.

Postprandial glucose, insulin and glucagon-like peptide-1 (GLP-1) levels following carbohydrate-first (CF), carbohydrate-last (CL) and sandwich (S) meal.

Pathophysiology and drug targets.

Outline of study protocol.

The Stomach in Diabetes: From Villain to Ally

(A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects. (A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects.

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 5.

Presentation transcript:

Glucose homeostasis: roles of insulin, glucagon, amylin, and GLP-1. Glucose homeostasis: roles of insulin, glucagon, amylin, and GLP-1. The multi-hormonal model of glucose homeostasis (nondiabetic individuals): in the fed state, amylin communicates through neural pathways (1) to suppress postprandial glucagon secretion (2) while helping to slow the rate of gastric emptying (3). These actions regulate the rate of glucose appearance in the circulation (4). *In animal models, amylin has been shown to dose-dependently reduced food intake and body weight (5). In addition, incretin hormones, such as GLP-1, glucose-dependently enhance insulin secretion (6) and suppress glucagon secretion (2) and, via neural pathways, help slow gastric emptying and reduce food intake and body weight (5). Stephen L. Aronoff et al. Diabetes Spectr 2004;17:183-190 ©2004 by American Diabetes Association